To address these limitations, the present study aimed to compare the efficacy and safety of osimertinib (alone or in combination) versus erlotinib (alone or in combination) in treatment-naïve adult patients with EGFR mutation-positive advanced or metastatic NSCLC through a comprehensive network meta-analysis. Here, EGFR is linked to non-small cell lung carcinoma.